Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.20
+4.9%
$0.22
$0.15
$13.00
$11.91MN/A5.53 million shs1.36 million shs
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
$1.34
+0.8%
$0.70
$0.11
$3.91
$43.54M11.0820.77 million shs4.24 million shs
Renovaro Inc. stock logo
RENB
Renovaro
$0.31
+3.1%
$0.32
$0.27
$2.10
$52.62M0.511.56 million shs1.17 million shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$4.97
+6.0%
$6.20
$2.02
$11.00
$62.83M1.89335,457 shs637,243 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
-0.59%-12.17%-11.13%-31.89%+18,689,900.00%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
+16.67%+17.70%+548.78%+731.25%+132,999,900.00%
Renovaro Inc. stock logo
RENB
Renovaro
+6.65%+2.63%-4.01%-26.59%-81.47%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
+1.19%-1.68%-37.83%-0.23%+2.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/AN/AN/AN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
1.0009 of 5 stars
0.02.00.00.01.93.30.6
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.179 of 5 stars
3.83.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abpro Holdings Inc. stock logo
ABP
Abpro
3.00
Buy$4.001,940.82% Upside
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
0.00
N/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
0.00
N/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.50
Strong Buy$60.001,107.24% Upside

Current Analyst Ratings Breakdown

Latest ABP, RENB, KLTO, and UNCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$90.00
4/21/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
4/11/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abpro Holdings Inc. stock logo
ABP
Abpro
$183K65.11N/AN/A($0.29) per share-0.68
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/A$0.04 per shareN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/A$0.89 per shareN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abpro Holdings Inc. stock logo
ABP
Abpro
-$7.23MN/A0.00N/AN/AN/A-198.95%N/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
-$6.15M-$0.36N/AN/AN/A-1,779.01%-275.01%N/A
Renovaro Inc. stock logo
RENB
Renovaro
-$88.43M-$0.77N/AN/AN/A-60.38%-47.04%N/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$36.73M-$5.10N/AN/AN/AN/A-277.30%-61.53%N/A

Latest ABP, RENB, KLTO, and UNCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025N/A
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A-$0.08N/A-$0.08N/AN/A
5/15/2025Q1 2025
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A-$0.08N/A-$0.08N/AN/A
5/14/2025Q1 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$1.40-$0.50+$0.90-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A
0.11
0.11
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A
0.29
0.29
Renovaro Inc. stock logo
RENB
Renovaro
N/A
0.13
0.13
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
1.64
1.64

Institutional Ownership

CompanyInstitutional Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
23.30%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
20.07%
Renovaro Inc. stock logo
RENB
Renovaro
71.41%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
20.80%
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
26.70%
Renovaro Inc. stock logo
RENB
Renovaro
21.72%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
10.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abpro Holdings Inc. stock logo
ABP
Abpro
1560.79 million48.14 millionN/A
Klotho Neurosciences, Inc. stock logo
KLTO
Klotho Neurosciences
N/A32.49 million23.82 millionN/A
Renovaro Inc. stock logo
RENB
Renovaro
20172.12 million134.74 millionOptionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
912.64 million11.29 millionNot Optionable

Recent News About These Companies

Unicycive hit with CRL on oxylanthanum carbonate NDA
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abpro stock logo

Abpro NASDAQ:ABP

$0.20 +0.01 (+4.87%)
As of 04:00 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Klotho Neurosciences stock logo

Klotho Neurosciences NASDAQ:KLTO

$1.34 +0.01 (+0.75%)
As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Renovaro stock logo

Renovaro NASDAQ:RENB

$0.31 +0.01 (+3.10%)
Closing price 04:00 PM Eastern
Extended Trading
$0.30 0.00 (-0.23%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$4.97 +0.28 (+5.97%)
Closing price 04:00 PM Eastern
Extended Trading
$4.99 +0.02 (+0.40%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.